Erectile Dysfunction Drugs Market to 2027 - Global Analysis and Forecasts By Product (Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/ staxyn (Vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (alprostadil), Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography
Report Code: TIPRE00007158 No. of Pages: 150 Category: Pharmaceuticals Status: Upcoming
Listen Report :
MARKET INTRODUCTION
Erectile dysfunction (ED) is the incapacity to get and continue an erection firm during sexual intercourse. Erectile dysfunction can occur due to various problems, such as a combination of physical and psychological issues that result in erectile dysfunction. The drugs for ED produces an erection sufficient to start intercourse in men. The Food and Drug Administration (FDA) suggested and approved various prescription drugs that can be taken orally to treat ED.
MARKET DYNAMICS
Erectile dysfunction drugs market is anticipated to grow in the forecast period owing to driving factors such as increasing adoption of a sedentary lifestyle with the related stress, growing elderly population, and chronic diseases such as heart diseases, and diabetes. Moreover, advanced healthcare infrastructure and increasing attentiveness towards health in emerging economies are also offering opportunities in the market growth during the forecast period.
MARKET SCOPE
The "Global Erectile Dysfunction Drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of erectile dysfunction drugs market with detailed market segmentation by product, distribution channel, and geography. The global erectile dysfunction drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading erectile dysfunction drugs market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global erectile dysfunction drugs market is segmented on the basis of product, distribution channel. Based on product, the market is segmented as Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/ staxyn (Vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (alprostadil), and Others. Based on distribution channel, the market is segmented as hospital pharmacies, retail pharmacies, and online pharmacies.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global erectile dysfunction drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The erectile dysfunction drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting erectile dysfunction drugs market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the erectile dysfunction drugs market in these regions.
The report covers key developments in the erectile dysfunction drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from erectile dysfunction drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for erectile dysfunction drugs in the global market. Below mentioned is the list of few companies engaged in the Erectile dysfunction drugs market.
The report also includes the profiles of key erectile dysfunction drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
Erectile dysfunction (ED) is the incapacity to get and continue an erection firm during sexual intercourse. Erectile dysfunction can occur due to various problems, such as a combination of physical and psychological issues that result in erectile dysfunction. The drugs for ED produces an erection sufficient to start intercourse in men. The Food and Drug Administration (FDA) suggested and approved various prescription drugs that can be taken orally to treat ED.
MARKET DYNAMICS
Erectile dysfunction drugs market is anticipated to grow in the forecast period owing to driving factors such as increasing adoption of a sedentary lifestyle with the related stress, growing elderly population, and chronic diseases such as heart diseases, and diabetes. Moreover, advanced healthcare infrastructure and increasing attentiveness towards health in emerging economies are also offering opportunities in the market growth during the forecast period.
MARKET SCOPE
The "Global Erectile Dysfunction Drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of erectile dysfunction drugs market with detailed market segmentation by product, distribution channel, and geography. The global erectile dysfunction drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading erectile dysfunction drugs market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global erectile dysfunction drugs market is segmented on the basis of product, distribution channel. Based on product, the market is segmented as Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/ staxyn (Vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (alprostadil), and Others. Based on distribution channel, the market is segmented as hospital pharmacies, retail pharmacies, and online pharmacies.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global erectile dysfunction drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The erectile dysfunction drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting erectile dysfunction drugs market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the erectile dysfunction drugs market in these regions.
The report covers key developments in the erectile dysfunction drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from erectile dysfunction drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for erectile dysfunction drugs in the global market. Below mentioned is the list of few companies engaged in the Erectile dysfunction drugs market.
The report also includes the profiles of key erectile dysfunction drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Ferring B.V.
- Bayer AG
- Eli Lilly And Company
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Pfizer, Inc.
- Metuchen Pharmaceuticals LLC
- Vivus, Inc.
- Dong-A Pharmaceutical Co., Ltd.
- Glaxosmithkline Plc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Erectile Dysfunction Drugs Market - By Product
1.3.2 Erectile Dysfunction Drugs Market - By Distribution Channel
1.3.3 Erectile Dysfunction Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ERECTILE DYSFUNCTION DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ERECTILE DYSFUNCTION DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ERECTILE DYSFUNCTION DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ERECTILE DYSFUNCTION DRUGS - GLOBAL MARKET OVERVIEW
6.2. ERECTILE DYSFUNCTION DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ERECTILE DYSFUNCTION DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. VIAGRA (SILDENAFIL CITRATE)
7.3.1. Overview
7.3.2. Viagra (sildenafil citrate) Market Forecast and Analysis
7.4. CIALIS (TADALAFIL)
7.4.1. Overview
7.4.2. Cialis (tadalafil) Market Forecast and Analysis
7.5. LEVITRA/ STAXYN (VARDENAFIL)
7.5.1. Overview
7.5.2. Levitra/ staxyn (Vardenafil) Market Forecast and Analysis
7.6. STENDRA/SPEDRA (AVANAFIL)
7.6.1. Overview
7.6.2. Stendra/Spedra (avanafil) Market Forecast and Analysis
7.7. ZYDENA (UDENAFIL)
7.7.1. Overview
7.7.2. Zydena (udenafil) Market Forecast and Analysis
7.8. VITAROS (ALPROSTADIL)
7.8.1. Overview
7.8.2. Vitaros (alprostadil) Market Forecast and Analysis
7.9. OTHERS
7.9.1. Overview
7.9.2. Others Market Forecast and Analysis
8. ERECTILE DYSFUNCTION DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. ERECTILE DYSFUNCTION DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Erectile Dysfunction Drugs Market Overview
9.1.2 North America Erectile Dysfunction Drugs Market Forecasts and Analysis
9.1.3 North America Erectile Dysfunction Drugs Market Forecasts and Analysis - By Product
9.1.4 North America Erectile Dysfunction Drugs Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Erectile Dysfunction Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Erectile Dysfunction Drugs Market
9.1.5.1.1 United States Erectile Dysfunction Drugs Market by Product
9.1.5.1.2 United States Erectile Dysfunction Drugs Market by Distribution Channel
9.1.5.2 Canada Erectile Dysfunction Drugs Market
9.1.5.2.1 Canada Erectile Dysfunction Drugs Market by Product
9.1.5.2.2 Canada Erectile Dysfunction Drugs Market by Distribution Channel
9.1.5.3 Mexico Erectile Dysfunction Drugs Market
9.1.5.3.1 Mexico Erectile Dysfunction Drugs Market by Product
9.1.5.3.2 Mexico Erectile Dysfunction Drugs Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Erectile Dysfunction Drugs Market Overview
9.2.2 Europe Erectile Dysfunction Drugs Market Forecasts and Analysis
9.2.3 Europe Erectile Dysfunction Drugs Market Forecasts and Analysis - By Product
9.2.4 Europe Erectile Dysfunction Drugs Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Erectile Dysfunction Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Erectile Dysfunction Drugs Market
9.2.5.1.1 Germany Erectile Dysfunction Drugs Market by Product
9.2.5.1.2 Germany Erectile Dysfunction Drugs Market by Distribution Channel
9.2.5.2 France Erectile Dysfunction Drugs Market
9.2.5.2.1 France Erectile Dysfunction Drugs Market by Product
9.2.5.2.2 France Erectile Dysfunction Drugs Market by Distribution Channel
9.2.5.3 Italy Erectile Dysfunction Drugs Market
9.2.5.3.1 Italy Erectile Dysfunction Drugs Market by Product
9.2.5.3.2 Italy Erectile Dysfunction Drugs Market by Distribution Channel
9.2.5.4 Spain Erectile Dysfunction Drugs Market
9.2.5.4.1 Spain Erectile Dysfunction Drugs Market by Product
9.2.5.4.2 Spain Erectile Dysfunction Drugs Market by Distribution Channel
9.2.5.5 United Kingdom Erectile Dysfunction Drugs Market
9.2.5.5.1 United Kingdom Erectile Dysfunction Drugs Market by Product
9.2.5.5.2 United Kingdom Erectile Dysfunction Drugs Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Erectile Dysfunction Drugs Market Overview
9.3.2 Asia-Pacific Erectile Dysfunction Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Erectile Dysfunction Drugs Market Forecasts and Analysis - By Product
9.3.4 Asia-Pacific Erectile Dysfunction Drugs Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Erectile Dysfunction Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Erectile Dysfunction Drugs Market
9.3.5.1.1 Australia Erectile Dysfunction Drugs Market by Product
9.3.5.1.2 Australia Erectile Dysfunction Drugs Market by Distribution Channel
9.3.5.2 China Erectile Dysfunction Drugs Market
9.3.5.2.1 China Erectile Dysfunction Drugs Market by Product
9.3.5.2.2 China Erectile Dysfunction Drugs Market by Distribution Channel
9.3.5.3 India Erectile Dysfunction Drugs Market
9.3.5.3.1 India Erectile Dysfunction Drugs Market by Product
9.3.5.3.2 India Erectile Dysfunction Drugs Market by Distribution Channel
9.3.5.4 Japan Erectile Dysfunction Drugs Market
9.3.5.4.1 Japan Erectile Dysfunction Drugs Market by Product
9.3.5.4.2 Japan Erectile Dysfunction Drugs Market by Distribution Channel
9.3.5.5 South Korea Erectile Dysfunction Drugs Market
9.3.5.5.1 South Korea Erectile Dysfunction Drugs Market by Product
9.3.5.5.2 South Korea Erectile Dysfunction Drugs Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Erectile Dysfunction Drugs Market Overview
9.4.2 Middle East and Africa Erectile Dysfunction Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Erectile Dysfunction Drugs Market Forecasts and Analysis - By Product
9.4.4 Middle East and Africa Erectile Dysfunction Drugs Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Erectile Dysfunction Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Erectile Dysfunction Drugs Market
9.4.5.1.1 South Africa Erectile Dysfunction Drugs Market by Product
9.4.5.1.2 South Africa Erectile Dysfunction Drugs Market by Distribution Channel
9.4.5.2 Saudi Arabia Erectile Dysfunction Drugs Market
9.4.5.2.1 Saudi Arabia Erectile Dysfunction Drugs Market by Product
9.4.5.2.2 Saudi Arabia Erectile Dysfunction Drugs Market by Distribution Channel
9.4.5.3 U.A.E Erectile Dysfunction Drugs Market
9.4.5.3.1 U.A.E Erectile Dysfunction Drugs Market by Product
9.4.5.3.2 U.A.E Erectile Dysfunction Drugs Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Erectile Dysfunction Drugs Market Overview
9.5.2 South and Central America Erectile Dysfunction Drugs Market Forecasts and Analysis
9.5.3 South and Central America Erectile Dysfunction Drugs Market Forecasts and Analysis - By Product
9.5.4 South and Central America Erectile Dysfunction Drugs Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Erectile Dysfunction Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Erectile Dysfunction Drugs Market
9.5.5.1.1 Brazil Erectile Dysfunction Drugs Market by Product
9.5.5.1.2 Brazil Erectile Dysfunction Drugs Market by Distribution Channel
9.5.5.2 Argentina Erectile Dysfunction Drugs Market
9.5.5.2.1 Argentina Erectile Dysfunction Drugs Market by Product
9.5.5.2.2 Argentina Erectile Dysfunction Drugs Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ERECTILE DYSFUNCTION DRUGS MARKET, KEY COMPANY PROFILES
11.1. FERRING B.V.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. BAYER AG
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. ELI LILLY AND COMPANY
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. MYLAN N.V.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. PFIZER, INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. METUCHEN PHARMACEUTICALS LLC
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. VIVUS, INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. DONG-A PHARMACEUTICAL CO., LTD.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. GLAXOSMITHKLINE PLC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Erectile Dysfunction Drugs Market - By Product
1.3.2 Erectile Dysfunction Drugs Market - By Distribution Channel
1.3.3 Erectile Dysfunction Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ERECTILE DYSFUNCTION DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ERECTILE DYSFUNCTION DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ERECTILE DYSFUNCTION DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ERECTILE DYSFUNCTION DRUGS - GLOBAL MARKET OVERVIEW
6.2. ERECTILE DYSFUNCTION DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ERECTILE DYSFUNCTION DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. VIAGRA (SILDENAFIL CITRATE)
7.3.1. Overview
7.3.2. Viagra (sildenafil citrate) Market Forecast and Analysis
7.4. CIALIS (TADALAFIL)
7.4.1. Overview
7.4.2. Cialis (tadalafil) Market Forecast and Analysis
7.5. LEVITRA/ STAXYN (VARDENAFIL)
7.5.1. Overview
7.5.2. Levitra/ staxyn (Vardenafil) Market Forecast and Analysis
7.6. STENDRA/SPEDRA (AVANAFIL)
7.6.1. Overview
7.6.2. Stendra/Spedra (avanafil) Market Forecast and Analysis
7.7. ZYDENA (UDENAFIL)
7.7.1. Overview
7.7.2. Zydena (udenafil) Market Forecast and Analysis
7.8. VITAROS (ALPROSTADIL)
7.8.1. Overview
7.8.2. Vitaros (alprostadil) Market Forecast and Analysis
7.9. OTHERS
7.9.1. Overview
7.9.2. Others Market Forecast and Analysis
8. ERECTILE DYSFUNCTION DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. ERECTILE DYSFUNCTION DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Erectile Dysfunction Drugs Market Overview
9.1.2 North America Erectile Dysfunction Drugs Market Forecasts and Analysis
9.1.3 North America Erectile Dysfunction Drugs Market Forecasts and Analysis - By Product
9.1.4 North America Erectile Dysfunction Drugs Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Erectile Dysfunction Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Erectile Dysfunction Drugs Market
9.1.5.1.1 United States Erectile Dysfunction Drugs Market by Product
9.1.5.1.2 United States Erectile Dysfunction Drugs Market by Distribution Channel
9.1.5.2 Canada Erectile Dysfunction Drugs Market
9.1.5.2.1 Canada Erectile Dysfunction Drugs Market by Product
9.1.5.2.2 Canada Erectile Dysfunction Drugs Market by Distribution Channel
9.1.5.3 Mexico Erectile Dysfunction Drugs Market
9.1.5.3.1 Mexico Erectile Dysfunction Drugs Market by Product
9.1.5.3.2 Mexico Erectile Dysfunction Drugs Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Erectile Dysfunction Drugs Market Overview
9.2.2 Europe Erectile Dysfunction Drugs Market Forecasts and Analysis
9.2.3 Europe Erectile Dysfunction Drugs Market Forecasts and Analysis - By Product
9.2.4 Europe Erectile Dysfunction Drugs Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Erectile Dysfunction Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Erectile Dysfunction Drugs Market
9.2.5.1.1 Germany Erectile Dysfunction Drugs Market by Product
9.2.5.1.2 Germany Erectile Dysfunction Drugs Market by Distribution Channel
9.2.5.2 France Erectile Dysfunction Drugs Market
9.2.5.2.1 France Erectile Dysfunction Drugs Market by Product
9.2.5.2.2 France Erectile Dysfunction Drugs Market by Distribution Channel
9.2.5.3 Italy Erectile Dysfunction Drugs Market
9.2.5.3.1 Italy Erectile Dysfunction Drugs Market by Product
9.2.5.3.2 Italy Erectile Dysfunction Drugs Market by Distribution Channel
9.2.5.4 Spain Erectile Dysfunction Drugs Market
9.2.5.4.1 Spain Erectile Dysfunction Drugs Market by Product
9.2.5.4.2 Spain Erectile Dysfunction Drugs Market by Distribution Channel
9.2.5.5 United Kingdom Erectile Dysfunction Drugs Market
9.2.5.5.1 United Kingdom Erectile Dysfunction Drugs Market by Product
9.2.5.5.2 United Kingdom Erectile Dysfunction Drugs Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Erectile Dysfunction Drugs Market Overview
9.3.2 Asia-Pacific Erectile Dysfunction Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Erectile Dysfunction Drugs Market Forecasts and Analysis - By Product
9.3.4 Asia-Pacific Erectile Dysfunction Drugs Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Erectile Dysfunction Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Erectile Dysfunction Drugs Market
9.3.5.1.1 Australia Erectile Dysfunction Drugs Market by Product
9.3.5.1.2 Australia Erectile Dysfunction Drugs Market by Distribution Channel
9.3.5.2 China Erectile Dysfunction Drugs Market
9.3.5.2.1 China Erectile Dysfunction Drugs Market by Product
9.3.5.2.2 China Erectile Dysfunction Drugs Market by Distribution Channel
9.3.5.3 India Erectile Dysfunction Drugs Market
9.3.5.3.1 India Erectile Dysfunction Drugs Market by Product
9.3.5.3.2 India Erectile Dysfunction Drugs Market by Distribution Channel
9.3.5.4 Japan Erectile Dysfunction Drugs Market
9.3.5.4.1 Japan Erectile Dysfunction Drugs Market by Product
9.3.5.4.2 Japan Erectile Dysfunction Drugs Market by Distribution Channel
9.3.5.5 South Korea Erectile Dysfunction Drugs Market
9.3.5.5.1 South Korea Erectile Dysfunction Drugs Market by Product
9.3.5.5.2 South Korea Erectile Dysfunction Drugs Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Erectile Dysfunction Drugs Market Overview
9.4.2 Middle East and Africa Erectile Dysfunction Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Erectile Dysfunction Drugs Market Forecasts and Analysis - By Product
9.4.4 Middle East and Africa Erectile Dysfunction Drugs Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Erectile Dysfunction Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Erectile Dysfunction Drugs Market
9.4.5.1.1 South Africa Erectile Dysfunction Drugs Market by Product
9.4.5.1.2 South Africa Erectile Dysfunction Drugs Market by Distribution Channel
9.4.5.2 Saudi Arabia Erectile Dysfunction Drugs Market
9.4.5.2.1 Saudi Arabia Erectile Dysfunction Drugs Market by Product
9.4.5.2.2 Saudi Arabia Erectile Dysfunction Drugs Market by Distribution Channel
9.4.5.3 U.A.E Erectile Dysfunction Drugs Market
9.4.5.3.1 U.A.E Erectile Dysfunction Drugs Market by Product
9.4.5.3.2 U.A.E Erectile Dysfunction Drugs Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Erectile Dysfunction Drugs Market Overview
9.5.2 South and Central America Erectile Dysfunction Drugs Market Forecasts and Analysis
9.5.3 South and Central America Erectile Dysfunction Drugs Market Forecasts and Analysis - By Product
9.5.4 South and Central America Erectile Dysfunction Drugs Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Erectile Dysfunction Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Erectile Dysfunction Drugs Market
9.5.5.1.1 Brazil Erectile Dysfunction Drugs Market by Product
9.5.5.1.2 Brazil Erectile Dysfunction Drugs Market by Distribution Channel
9.5.5.2 Argentina Erectile Dysfunction Drugs Market
9.5.5.2.1 Argentina Erectile Dysfunction Drugs Market by Product
9.5.5.2.2 Argentina Erectile Dysfunction Drugs Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ERECTILE DYSFUNCTION DRUGS MARKET, KEY COMPANY PROFILES
11.1. FERRING B.V.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. BAYER AG
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. ELI LILLY AND COMPANY
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. MYLAN N.V.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. PFIZER, INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. METUCHEN PHARMACEUTICALS LLC
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. VIVUS, INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. DONG-A PHARMACEUTICAL CO., LTD.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. GLAXOSMITHKLINE PLC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies
1. Ferring B.V.
2. Bayer AG
3. Eli Lilly And Company
4. Teva Pharmaceutical Industries Ltd.
5. Mylan N.V.
6. Pfizer, Inc.
7. Metuchen Pharmaceuticals LLC
8. Vivus, Inc.
9. Dong-A Pharmaceutical Co., Ltd.
10. Glaxosmithkline Plc.
1. Ferring B.V.
2. Bayer AG
3. Eli Lilly And Company
4. Teva Pharmaceutical Industries Ltd.
5. Mylan N.V.
6. Pfizer, Inc.
7. Metuchen Pharmaceuticals LLC
8. Vivus, Inc.
9. Dong-A Pharmaceutical Co., Ltd.
10. Glaxosmithkline Plc.